\r\n\t \r\n\t \r","showSummary":null,"url":"/pharmacy/kaloroma-retail-clinics-represent-big-business-ivd-products-poc-testing","date":"2016-09-28T00:00:00","author":{"email":null,"uname":"Anonymous","firstName":null,"lastName":null,"bio":null,"title":null,"picture":null,"phone":null,"contactForm":null},"digitalEdition":null,"sponsored":false,"taggedPro":null,"teaserImage":{"id":59096,"url":"https://assets1.drugstorenews.com/styles/secondary_articles_short/s3/teaser_image_386348.jpg?itok=MUowDMJN","width":767,"height":575,"alt":null},"topics":[{"name":"News","url":"/news"},{"name":"RETAIL NEWS","url":"/retail-news"},{"name":"PHARMACY","url":"/pharmacy"},{"name":"Retail Clinics","url":"/retail-clinics"}],"attachedFiles":[]},{"title":"Convenient Care Association chief to helm Woods Resources","id":27122,"bundle":"article","summary":null,"showSummary":null,"url":"/pharmacy/convenient-care-association-chief-helm-woods-resources","date":"2016-09-27T00:00:00","author":{"email":null,"uname":"Anonymous","firstName":null,"lastName":null,"bio":null,"title":null,"picture":null,"phone":null,"contactForm":null},"digitalEdition":null,"sponsored":false,"taggedPro":null,"teaserImage":{"id":59082,"url":"https://assets1.drugstorenews.com/styles/secondary_articles_short/s3/teaser_image_386332.jpg?itok=pPbmrz2i","width":767,"height":575,"alt":null},"topics":[{"name":"News","url":"/news"},{"name":"RETAIL NEWS","url":"/retail-news"},{"name":"PHARMACY","url":"/pharmacy"},{"name":"Retail Clinics","url":"/retail-clinics"}],"attachedFiles":[]},{"title":"FDA approves Janssen’s Invokamet XR","id":27176,"bundle":"article","summary":"
\r\n\tSILVER SPRING, Md. — The Food and Drug Administration has approved Janssen Pharmaceuticals’ Invokamet XR, a once-daily, extended-release combination therapy of Invokana (canagliflozin) and metformin, the company announced Wednesday. The drug is indicated as a first-line treatment to improve blood glucose control in adults with Type 2 diabetes alongside diet and exercise.
\r\n
\r\n\t
\r\n
\r","showSummary":null,"url":"/pharmacy/fda-approves-janssens-invokamet-xr","date":"2016-09-21T00:00:00","author":{"email":null,"uname":"Anonymous","firstName":null,"lastName":null,"bio":null,"title":null,"picture":null,"phone":null,"contactForm":null},"digitalEdition":null,"sponsored":false,"taggedPro":null,"teaserImage":{"id":59029,"url":"https://assets1.drugstorenews.com/styles/secondary_articles_short/s3/teaser_image_386276.jpg?itok=aUuiokp4","width":767,"height":575,"alt":null},"topics":[{"name":"News","url":"/news"},{"name":"PHARMACY","url":"/pharmacy"},{"name":"Branded","url":"/branded"},{"name":"Retail Clinics","url":"/retail-clinics"},{"name":"Diabetes","url":"/diabetes"}],"attachedFiles":[]},{"title":"Pfizer launches Moodivator app for patients with depression","id":27235,"bundle":"article","summary":"
\r\n\tNEW YORK — Pfizer has launched a new app, Moodivator, aimed at helping to motivate and encourage patients with depression. The app is designed to help patients track their mood, set goals and establish routines as a complement to their treatment for depression, which can include talk therapy, medication and other approaches.
SILVER SPRING, Md. — The Food and Drug Administration has approved Orexo’s Zubsolv (buprenorphine 0.7 mg/naloxone 0.18 mg) sublingual tablets, the company announced Thursday. The drug is indicated to treat patients with opioid dependence.
With this approval, Orexo now has FDA approval for six dosage strength tablets: 11.4 mg buprenorphine/2.9 mg naloxone, 8.6 mg/2.1 mg, 5.7 mg/1.5 mg, 2.9 mg/0.71 mg, 1.4 mg/0.36 mg and 0.7 mg/0.18 mg.
DUBLIN, Ireland — Health Canada on Tuesday approved naloxone hydrochloride nasal spray, a nasal delivery method for the opioid overdose medication, which Adapt Pharma said it would market as Narcan Nasal Spray.
NEW YORK — A recent survey from CityMD Urgent Care is finding that a lot of people aren’t planning on getting flu shots, and among millennials, slightly more than half of them don’t plan on getting vaccinated against the flu this year.
ATLANTA — In its Morbidity and Mortality Weekly Report, the Centers for Disease Control and Prevention break down a survey about influenza vaccination among healthcare professionals, noting that employer vaccine requirements or on-site vaccination can help achieve better coverage.
ST. PAUL, Minn. — Pharmacy benefit manager Prime Therapeutics recently analyzed pharmacy claims for short- and long-acting opioids, finding a decrease in short-acting opioid claims and an increase in long-acting opioid claims. The review of 15 million commercially insured members found an overall 3.9% decrease in opioid claims from 2014 to 2015.
NEW YORK - With the number of U.S. clinics located within retail locations exceeding 2,000, they have become an important target for in vitro diagnostic products and point-of-care testing, Kalorama Information reported Wednesday.
SILVER SPRING, Md. — The Food and Drug Administration has approved Janssen Pharmaceuticals’ Invokamet XR, a once-daily, extended-release combination therapy of Invokana (canagliflozin) and metformin, the company announced Wednesday. The drug is indicated as a first-line treatment to improve blood glucose control in adults with Type 2 diabetes alongside diet and exercise.
NEW YORK — Pfizer has launched a new app, Moodivator, aimed at helping to motivate and encourage patients with depression. The app is designed to help patients track their mood, set goals and establish routines as a complement to their treatment for depression, which can include talk therapy, medication and other approaches.